Condition: Neuromyelitis Optica Spectrum Disorders · Sponsor: Tongji Hospital
This is a single-center, randomized, open-label, placebo-controlled, dose-escalation trial. The objective of this research is to evaluate the safety, tolerability, and efficacy of intrathecal administration of human-induced neural stem cell-derived extracellular vesicles (NouvSoma001) for the treatment of neuromyelitis optica spectrum disorders.
This description comes directly from the study's public registry record.
Chuan Qin, MD · 86-27-83663337 · qinchuan712@126.com
Chuan Qin, MD · 86-27-83663332 · chuanqin@tjh.tjmu.edu.cn
Always discuss trial participation with your own doctor first.
| Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06620809